Morphine

DEA Proposal

On August 7, 2017 the U.S. Drug Enforcement Agency (DEA) published a proposal which would establish a production limit on the manufacturing of several controlled substances starting in 2018. This reduction is supported by data obtained from IMS Health and will impact the production of commonly prescribed Schedule II opioid painkillers such as:

  • Oxycodone
  • Hydrocodone
  • Oxymorphone
  • Hydromorphone
  • Morphine
  • Codeine
  • Meperidine
  • Fentanyl

According to Acting Administrator Chuck Rosenberg, “Physicians, pharmacists, and patients must recognize the inherent risks of these powerful medications, especially for long-term use.” Moreover, “more states are mandating use of prescription drug monitoring programs, which is good, and that has prompted a decrease in opioid prescriptions,” he said.

As published in the Federal Register, the DEA determined the need for a production limit as a result of several factors, including:

  • Disposal of each class of chemical by manufacturers and chemical importers
  • National rate of net disposal
  • Trends in inventory accumulation
  • Projected future demand

Curbing the production of these drugs is one more tool that’s being deployed in conjunction with the National Prescription Drug Take-Back Day, treatment programs, and prescription drug monitoring. Together, they should help to reduce the risk of abuse associated with these dangerous substances.

For more information about Employer Solutions, visit our website or contact us online.

The Quest Diagnostics Drug Testing Index™ (DTI) reveals insights into patterns of drug use among the American workforce. It has been published annually for more than 25 years as a public service for government, employers, policymakers, media, and the general public. This year’s report will be presented at the Drug and Alcohol Testing Industry Association (DATIA) annual conference, a gathering of industry professionals focused on safety, regulatory affairs, ethics, and workplace drug testing education from all over the world.

In examining the latest data, Barry Sample, Ph.D., Senior Director of Science and Technology at Quest Diagnostics, said, “This year’s findings are remarkable because they show increased rates of drug positivity for the most common illicit drugs across virtually all drug test specimen types and in all testing populations.” He noted the following key findings from millions of workplace drug test results.

  • Overall positivity in urine drug testing among the combined U.S. workforce in 2016 was 4.2 percent, a five percent relative increase over last year’s rate of 4.0 percent, and the highest annual positivity rate since 2004 (4.5 percent).
  • Cocaine, marijuana, and methamphetamine use is up broadly among the U.S. workforce across multiple drug test specimen types and testing populations.
  • Cocaine positivity increased 12 percent in 2016, reaching a seven-year high of 0.28 percent.
  • The positivity rate for cocaine in post-accident urine drug tests was more than twice that of pre-employment urine drug tests in both the federally-mandated, safety-sensitive and the general U.S. workforces.
  • In Colorado and Washington, the overall urine positivity rate for marijuana outpaced the national average in 2016 for the first time since the recreational statutes took effect.
  • Year over year marijuana positivity increased nearly 75 percent in oral fluid testing. In addition, positivity increased in both urine and hair testing in the general U.S. workforce.
  • Between 2012 and 2016, methamphetamine positivity climbed 64 percent in the general U.S. workforce and 14 percent among federally-mandated, safety-sensitive workers.
  • Heroin detection, indicated by the presence of the 6-acetylmorphine (6-AM) metabolite, plateaued in the general U.S. workforce while prescription opiate detection declines.

“Once again, the DTI statistics reveal the on-going threat to workplace safety posed by substance abuse. While the national dialogue swirls around marijuana and opiate issues, we find cocaine—a substance with well-established dangers—continuing its troubling upswing not just in the general workforce, but in safety-sensitive jobs with federally-mandated testing,” said Matt Nieman, General Counsel, Institute for a Drug-Free Workplace and Principal, Jackson Lewis P.C. “That positive test results for cocaine persist, let alone are increasing, should serve as a reminder to employers and employees that there is no substitute for vigilance in any effective effort to thwart the potential impacts of workplace substance abuse.”

Along with this year’s data, we are offering an interactive map to illustrate overall positivity and positivity by drug for the past 10 years in urine testing. Users can search by both zip code and year for six illicit drugs: 6-AM (heroin metabolite), amphetamines, cocaine, marijuana, opiates, and PCP at QuestDiagnostics.com/DrugMap.

Workplace drug testing promotes a safe, healthy and productive environment for employees. Our analysis suggests that employers committed to creating a safe, drug-free work environment should be aware of the potential for drug use among their workforce.

Media coverage for the Drug Testing Index includes an exclusive story by The Wall Street Journal. Other press featuring the DTI includes: The Washington Post, CNBC’s Closing BellTIME magazineFortune, CBS Money WatchViceMarketWatchThe Chicago Tribune, Facility Safety Management, Business InsuranceInsurance Journal, Daily Republic, FOX Denver,  Newsday, NJBIANew Jersey’s NJ.comPittsburgh Post-Gazette, North Nevada Business Weekly, Dayton Daily News, Brevard Times, The National Law Review, PoliticoThe TruckerHR DiveMedical Laboratory Observer: LabLineCrime Report, Drug ChronicleSteelers LoungeSector PublishingDaily Caller, Newsmax Wires, RTBulk Transporter, Lexology, Daily Chew, NCASJunior College, Industry Week, Salon, ExamOne blogWSJ: The 10-Point, Construction Equipment, EHS Today, Kansas City Star, Baltimore Sun, Hartford Business Journal, USA Today: LouisvilleHuman Resources Executive, Society for Human Resources Management (SHRM), and USA TODAY Snapshot.

In addition, the Jimmy Kimmel Live show asked cited Quest Diagnostics data and in its Pedestrian Question segment asked people if they have ever been high at work.

Read the full press release for the latest DTI data as well as drug testing news and resources.

Download our new Quest Diagnostics Drug Testing Index brochure and the this year’s DTI infographics.

For more information about drug testing, visit our QuestDiagnostics.com/DTI or contact us online.

Drug Positivity Rises in the Railroad Industry

September 19, 2016Drug Testing

Drug testing has some early origins in the railroad industry. In 1987, two trains collided in Chase, Maryland killing 12 and making it the deadliest crash in Amtrak’s history. After learning that the crew of the train that failed to stop tested positive for marijuana, the Federal Railroad Administration (FRA) swiftly overhauled its drug and alcohol […]

Read the full article →

Spotlight on the Prescription Drug Epidemic

June 16, 2016News

Autopsy results released earlier this month confirmed that a fentanyl overdose was the cause of death for 57 year old, multi-platinum recording artist – Prince. The death of such a prominent pop culture figure generated media headlines across the world, helping to bring public awareness about the prescription drug epidemic our country is facing. MarketWatch […]

Read the full article →

Challenging the Poppy Seed Defense

October 16, 2015News

The “poppy seed defense” or the claim that ingesting poppy seeds is the reason for a failed drug test has long been used to challenge drug test results. A Seinfeld episode brought it into the mainstream with a story line where Elaine Benes tests positive for opium on her company’s urine drug test and blames […]

Read the full article →